The study, which was published in the New England Journal of Medicine, evaluated rifaximin, a minimally absorbed antibiotic, to see its effectiveness in treating IBD. Results from the study showed that patients who were assigned to take rifaximin reported significantly more relief of global IBS symptoms during the first four weeks after treatment than the control group. More patients in the rifaximin group than the control group also reported relief from bloating.
Read the study about rifaximin and IBD.
Read other coverage about GI treatments:
– Study: More Colonoscopy Screening Options Confuse Patients
– Research Suggests High Endoscopy Completion Rates Tied to Fewer Missed Colorectal Cancers
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.